View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Laboratorio Reig Jofre S.A.: 1 director

A director at Laboratorio Reig Jofre S.A. bought 15,845 shares at 2.700EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales...

Reig Jofre: EBITDA maintains its growth in 1H20 (+40%) driven by sales (+25%) and cost efficiencies Growth in sales and EBITDA fuelled by the COVID-19 effect and the Bioibérica acquisition The key features are organic growth of +10%, a higher EBITDA margin and the COVID-19 vaccine Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: EBITDA increased +43% in 1Q20 fuelled by sales (+26%) and ...

Growth in sales and EBITDA accelerated in 1Q20 fuelled by the COVID-19 effect The key features are organic growth of +10%, a higher EBITDA margin and lower capex Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: EBITDA (adj.) +17% in 2019 and guidance is 2x in a five-ye...

Growth in sales and adjusted EBITDA accelerated in 2019 after a strong 4Q19 Higher margins coupled to lower capex in the coming years to boost free cash flow Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: A sound 9M19 but TP cut on concerns about Bioibérica

Reig Jofre: A sound 9M19 but TP cut on concerns about Bioibérica Growth in sales and adjusted EBITDA accelerated in 9M19 after a strong 3Q19 Bioibérica: Medicaments to treat arthrosis may no longer be subsidized in Spain Valuation: Our target price is cut to €3.80/share (from €3.92/share)

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 2Q19 results grow 3% in sales and net profit

Reig Jofre: 2Q19 results grow 3% in sales and net profit Sales in 1H19 increased +3%, but sales and earnings dipped in 2Q19 from 1Q19 An equity issue in 2Q19 to prepare for an acquisition that closed in July 2019 Net debt falls sharply following the equity increase but is set to increase again in 3Q19 Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: An undiscovered pharma stock

Reig Jofre: An undiscovered pharma stock A pharma group focused on injectables Capacity additions and new launches to generate growth in sales Margin expansion Acquired a portfolio from Bioibérica in 3Q19 Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 1Q19 results: A promising start of the year

Reig Jofre: 1Q19 results: A promising start of the year Sales in 1Q19 increased +6.0% yoy Net profit increased +8.5% Leverage is moderate at 1.8x EBITDA Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 2018 results: A promising outlook derived from capacity ad...

Reig Jofre: 2018 results: A promising outlook derived from capacity additions Sales in 4Q18 increased +13.2% qoq Net profit increased +5.0% in 2018 Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 9M18 results: Sales increased +11.5% and margins expanded

Reig Jofre: 9M18 results: Sales increased +11.5% and margins expanded Sales in 3Q18 increased +21.3% yoy Higher margins, superior growth in results Capex drove debt up Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: 1H18 results feature double digit growth in sales

Reig Jofre: 1H18 results feature double digit growth in sales Sales in 1H18 increased +7.4%... …and the gross margin widened by 3.1pp Margin expansion Upgrading its plants Valuation

Pedro Echeguren
  • Pedro Echeguren

Reig Jofre: An undiscovered pharma stock

Reig Jofre: An undiscovered pharma stock A pharma group focused on injectables Capacity additions and new launches to generate growth in sales Margin expansion Valuation

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch